At February’s third annual Texas Forum on Blood Cancers, Louis J. DeGennaro, PhD and chief scientific officer for The Leukemia & Lymphoma Society (LLS), stressed the need for more clinical trials for blood cancer patients.
“Companies may have drugs on the shelf that are approved for other cancers and may work in blood cancers, but haven’t been tested because of lack of money and lack of enough patients,” said DeGennaro at the opening session, “Accelerating the Development of New Blood Cancer Therapies.”
In case you didn’t know, LLS is working hard on making sure that more clinical trials are available to blood cancer patients by way of the Therapy Acceleration Program, otherwise known as TAP. The goal of the program is to bypass some of the hurdles that have typically been in place, and to make sure that patients have access to the therapies they need sooner rather than later. The patient can still expect to receive high quality treatment – it’s just going to be there sooner, which can be critical for those who are living with fast-acting cancers.
Learn more about the LLS Therapy Acceleration Program on www.LLS.org and find out more about clinical trials at www.LLS.org/clinicaltrials. Read more about the Forum in Dallas at www.curetoday.com.
